Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 6:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2161–2184 of 21,991 matching trials from the live ClinicalTrials.gov search.

Filters: Recruiting Clear all

Conditions: Chronic Kidney Diseases, Pediatric Kidney Disease
Interventions: Empagliflozin 10 MG; Drug
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 12 Years to 25 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: COVID-19
Interventions: Bronchoscopies and Bronchoalveolar Lavages (BALs), Chest Tomography (CT), Electrocardiogram (ECG), Pulmonary function tests (PFTs), 6 minute walk test (6MWT); Procedure · Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Diabetic Retinopathy (DR)
Interventions: PRONTO-EYE; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Gout, Gouty Arthritis
Interventions: Pharmacist-Led; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 5
States / cities: Omaha, Nebraska • Portland, Oregon • Philadelphia, Pennsylvania + 2 more

Conditions: Acute Myeloid Leukemias
Interventions: Revumenib, Placebo, Intensive Chemotherapy Regimen; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 468 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 11
States / cities: Goodyear, Arizona • Duarte, California • Farmington, Connecticut + 8 more

Conditions: Non-small Cell Lung Cancer
Interventions: Pumitamig, Docetaxel; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Birmingham, Alabama • Tampa, Florida • Elizabethtown, Kentucky + 2 more

Conditions: Sickle Cell Disease, Sickle Cell Anemia, Osteonecrosis, Ischemic Necrosis, Avascular Necrosis
Interventions: Alendronate Sodium; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Rotator Cuff
Interventions: Muscle Fiber Fragments (MFFs); Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 40 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Burns, Second Degree Burn, Wounds and Injuries
Interventions: Drug: 4-Aminopyridine, Placebo; Drug · Other
Lead sponsor: John Elfar; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Healthy Volunteer, Prostate Cancer, Head and Neck Cancer, Esophageal Cancer, Genitourinary Cancer, Sarcoma, Breast Cancer, Colon Cancer, Gastrointestinal Cancer, Solid Tumor Cancer, Lung Cancer, Skin Cancer, Melanoma
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Facet Joints; Degeneration, Back Pain, Facet Joint Pain
Interventions: Alocyte low dose, Alocyte medium dose, Alocyte high dose; Drug
Lead sponsor: Alimorad Farshchian; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: North Miami, Florida

Conditions: Benign Prostatic Hyperplasia
Interventions: Medical Management, Surgical Management; Other
Lead sponsor: Northwestern University; Other
Eligibility: 50 Years and older · Male only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Glenview, Illinois

Conditions: Subjects Treated With Busulfan
Interventions: MyCare Oncology Busulfan Assay Kit; Diagnostic Test
Lead sponsor: Saladax Biomedical, Inc.; Industry
Eligibility: Not listed
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Chicago, Illinois • New Brunswick, New Jersey • Houston, Texas

Conditions: Solid Tumors
Interventions: SAR444881, Cemiplimab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Mycobacterium Avium Complex Pulmonary Disease
Interventions: Not listed
Lead sponsor: Radboud University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Urothelial Carcinoma Bladder
Interventions: Reproductive organ sparing radical cystectomy, Radical cystectomy; Procedure
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Chronic Heart Failure, Iron Deficiencies
Interventions: Ferric Derisomaltose; Drug
Lead sponsor: Pharmacosmos A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Hematologic Neoplasms
Interventions: JNJ-95804306, AML SoC, CLL/SLL SoC; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 6
States / cities: Indianapolis, Indiana • Grand Rapids, Michigan • Piscataway, New Jersey + 3 more

Conditions: Bone Graft; Complications, ACL Injuries
Interventions: autologous bone grafts, Demineralized bone matrix (DBM); Procedure · Other
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 40 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Phoenix, Arizona • Scottsdale, Arizona

Conditions: Ischemic Left Ventricle Systolic Dysfunction, Multivessel Coronary Artery Disease
Interventions: Cardiac Magnetic Resonance Imaging; Diagnostic Test
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 3
States / cities: Brooklyn, New York • Flushing, New York • New York, New York

Conditions: Acute Myeloid Leukemia
Interventions: Biospecimen Collection, Laboratory Biomarker Analysis; Procedure · Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Traumatic Brain Injury
Interventions: Physical therapy; Other
Lead sponsor: Craig Hospital; Other
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Englewood, Colorado

Conditions: Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, CT-guided Stereotactic Body Radiation Therapy, Inter-fraction Adaptation of Treatment Plan, Magnetic Resonance Imaging, MRI-guided Stereotactic Body Radiation Therapy, Survey Administration; Procedure · Radiation · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Stroke
Interventions: Virtual-reality based dance training; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 90 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 2
States / cities: Chicago, Illinois

Search by objective public record fields.

Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease

A Study of Post COVID-19 Mechanisms for Chronic Lung Sequelae

Using Implementation Science to Adapt a Targeted Transportation Intervention for Patients With Diabetic Retinopathy (PRONTO-EYE)

Pharmacist-Led Treat-to-Target Urate Lowering Therapy in Patients With Gout

Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

Alendronate for Osteonecrosis in Adults With Sickle Cell Disease

Muscle Fiber Fragments for Improved Function of Rotator Cuff Musculature Following Rotator Cuff Repair

4-Aminopyridine to Treat Skin Burns

Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors

Dose Escalation Pilot Study to Evaluate the Safety of Alocyte for the Treatment of Facetogenic Back Pain

Enhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia Using Patient-Reported Outcomes

Busulfan Sample Collection Study

Phase II Biomarker Study of BND-22 in Combination With Cemiplimab in Solid Tumors

A Prospective, Multicenter, Single-arm MAC-PD Cohort: a NTM-NET and ESGMYC Collaborative Study

Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy

Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure

A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

Radiographic Findings and Clinical Outcomes After Bone Grafting Patellar Defect in ACL Reconstruction

STICH3C Cardiac Magnetic Resonance Observational Study

Characterization of T-cell Repertoire in Patients With Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant

High Intensity Step Training After Traumatic Brain Injury

Image-Guidance and Online Adaptation With Stereotactic Body Radiation Therapy for the Treatment of Localized Prostate Cancer, MANTICORE Trial

Alternative Therapies for Improving Physical Function in Individuals With Stroke